T cell immunotherapies, notably chimeric-antigen receptor T (CAR-T) cells against CD19 or CD22 on acute lymphoblastic leukaemia (ALL) blasts, have demonstrated the potential to generate clinically significant immune responses in haematological malignancies [1]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.